BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12585651)

  • 1. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Weber BL
    Oncogene; 2006 Sep; 25(43):5825-31. PubMed ID: 16998496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk reduction works for BRCA mutation carriers--with heavy costs.
    Vanchieri C
    J Natl Cancer Inst; 2005 Jul; 97(14):1032-3. PubMed ID: 16030299
    [No Abstract]   [Full Text] [Related]  

  • 6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
    Domchek SM; Rebbeck TR
    LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
    Agnantis NJ; Paraskevaidis E; Roukos D
    Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
    [No Abstract]   [Full Text] [Related]  

  • 10. Reproductive issues for women with BRCA mutations.
    Friedman LC; Kramer RM
    J Natl Cancer Inst Monogr; 2005; (34):83-6. PubMed ID: 15784831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
    Matloff ET; Barnett RE; Bober SL
    Cancer J; 2009; 15(1):15-8. PubMed ID: 19197168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of preventive measures among BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
    Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
    Heisey RE; Carroll JC; Warner E; McCready DR; Goel V
    Can Fam Physician; 1999 Jan; 45():114-24. PubMed ID: 10889864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hereditary breast cancer: treatment and prevention].
    Ejlertsen B; Gerdes AM
    Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
    Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of BRCA genes in hereditary breast and ovarian cancer.
    Radice P
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):9-12. PubMed ID: 12585647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for ovarian cancer prevention.
    Dann RB; Kelley JL; Zorn KK
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.